Another week has passed and hump day is here again. In the past week, two of my deep-in-the-money calls hit for $1,000 gains.

British Petroleum

(BP) - Get Report

hit its strike price on the July 50 call and

Hercules Offshore

(HERO)

quickly came to fruition, nailing the July 20 position.

Johnson & Johnson

(JNJ) - Get Report

is a selection that has yet to hit its strike price, but its current price presents a prime opportunity to double down and increase the profit potential.

After my

March 7 column, I bought 10 contracts of the July 55 calls at $7.60, when the stock was trading around $61.70. Johnson & Johnson has yet to regain ground after the decline that preceded that trade; the stock has reached a new entry point, as there should be support near the $60 level.

The stock closed Tuesday at $60.03. As a result, I will be placing an order for 10 more July 55s, with a limit order at $5.70. In a slight twist from the usual, I will be keeping my GTC strike price at its original level of $8.60, because the potential of this company is particularly strong.

Health care expenditures nationwide have increased by almost 10% for each year in the past decade, to the point where health care now accounts for 16% of the nation's GDP, according to the National Coalition on Health Care. The industry is projected to continue growing at nearly the same rate, and Johnson & Johnson is in a great position to benefit.

Not only is the company well positioned for growth at home, it is also well established and growing internationally. Growth in economies in Europe and Asia has outpaced the U.S., and with more than 200 companies in 50 different countries under its umbrella, Johnson & Johnson can capitalize.

Due to the enormity of the company, changes in one aspect of Johnson & Johnson's business will have limited impact on the company as a whole. Unlike some of the smaller pharmaceutical companies, its price stability does not depend on the approval of particular drugs, but rather depends largely on the performance of the health care industry as a whole.

This makes the company a particularly attractive option in light of the market volatility this past month. Although no company is completely immune from a bear market, Johnson & Johnson should continue to be an attractive investment.

Another order I'm placing is for 20

Amgen

(AMGN) - Get Report

July 55s at $4.70. The stock has crept closer to the $56.20 buy level

I noted here.

As I noted above, it's Wednesday, which means it's time for the Stat Book. Here you go.

Remember, life is a journey; Enjoy the ride.

At the time of publication, Dykstra was long JNJ and AMGN.

Nicknamed "Nails" for his tough style of play during his Major League Baseball career, Lenny Dykstra was an integral member of the powerful Mets of the mid-1980s, including the world champion 1986 squad, and the Phillies in the early 1990s.

Today, Dykstra manages his own stock portfolio and serves as president of several of his privately held companies, including car washes; a partnership with Castrol in "Team Dykstra" Quick Lube Centers; a state-of-the-art ConocoPhillips fueling facility; a real estate development company; and a new venture to develop several "I Sold It on eBay" stores throughout high-demographic areas of Southern California.